Program
obrixtamig
Also written as “Obrixtamig”, “BI 764532” and “Obrixtamig - parenteral 1”.
In Boehringer Ingelheim's pipeline, DLL3/CD3 T-cell engager
. Its studies are mostly in Small Cell Lung Carcinoma · Glioma, led by Boehringer Ingelheim.
Furthest: phase 3, since Apr 16, 202611 company-led studies, 11 open or runningNext primary completion: Dec 15, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 1111 open or running | phase 3since Apr 16, 2026 | Jun 10, 2020 | Dec 15, 2026phase 1 · NCT05963867 |
- Named in Boehringer Ingelheim’s own pipeline as
Obrixtamig (BI 764532)
, phase 3, as of Aug 2026 (source).
Also a collaborator on its studies: BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2020First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT04429087 · 306 enrolled · United States, Germany, Japan and more
- May 22, 2023Phase 2 study in Small Cell Lung CarcinomaNCT05882058 · 204 planned · United States, Belgium, Bulgaria and more
- May 25, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05879978 · 45 enrolled · Belgium, France, Germany and more
- Jun 15, 2023Phase 1 study in GliomaNCT05916313 · 20 planned · United States, Austria, Germany and more
- Jul 18, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05963867 · 12 planned · Netherlands
- Aug 7, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05990738 · 69 enrolled · United States, France, Germany and more
- Oct 5, 2023Phase 1 study in Small Cell Lung CarcinomaNCT06077500 · 46 enrolled · United States, Belgium, France and more
- Apr 16, 2026Phase 3 study in Extrapulmonary Neuroendocrine Cancer (epNEC)Phase 3 reachedNCT07544654 · 390 planned · United States, Argentina, Australia and more
- Jul 13, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07707895 · 60 planned · United States, Australia, Belgium and more
- Sep 22, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07843940 · 55 planned · United States, Australia, Belgium and more
- Nov 5, 2026Phase 3 study in Advanced CancerNCT07929051 · 68 planned · Belgium, France, Germany and more
Ahead
- Dec 15, 2026Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05963867
- Mar 30, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05990738
- Mar 31, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06077500
- Aug 9, 2027Primary completion: phase 1 study in GliomaNCT05916313
TargetBeta
“DLL3/CD3 T-cell engager”the company's pipeline, read by Claude · source
“A bispecific T-cell engager antibody directed against both the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07929051Advanced Cancer · Belgium, France, Germany and more | 3 | Not yet recruiting | Jul 3, 2028 | 68 |
| NCT07843940Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Recruiting | Apr 17, 2030 | 55 |
| NCT07707895Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Recruiting | Apr 26, 2030 | 60 |
| NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC) · United States, Argentina, Australia and more | 3 | Recruiting | Dec 13, 2029 | 390 |
| NCT06077500Small Cell Lung Carcinoma · United States, Belgium, France and more | 1 | Active, not recruiting | Mar 31, 2027 | 46 |
| NCT05990738Small Cell Lung Carcinoma · United States, France, Germany and more | 1 | Active, not recruiting | Mar 30, 2027 | 69 |
| NCT05963867Small Cell Lung Carcinoma · Netherlands | 1 | Recruiting | Dec 15, 2026 | 12 |
| NCT05916313Glioma · United States, Austria, Germany and more | 1 | Recruiting | Aug 9, 2027 | 20 |
| NCT05879978Small Cell Lung Carcinoma · Belgium, France, Germany and more | 1 | Active, not recruiting | Jun 11, 2025 | 45 |
| NCT05882058Small Cell Lung Carcinoma · United States, Belgium, Bulgaria and more | 2 | Recruiting | Dec 17, 2027 | 204 |
| NCT04429087Small Cell Lung Carcinoma · United States, Germany, Japan and more | 1 | Active, not recruiting | Aug 31, 2026 | 306 |
How it is read
Names in the registry
- “Obrixtamig”, 5 entries
- “BI 764532”, 4 entries
- “Obrixtamig - parenteral 1”, 1 entry
- “Obrixtamig - parenteral 2”, 1 entry
- “BI 764532, dose 1”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 8 studies
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.